Enrolling By InvitationNCT04987229
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Medication studyAges 10–17Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 10 years to 17 years.
- Listed locations
- Dothan and 34 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 22, 2021
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 236
- Sponsor
- Alkermes, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Argentina, Brazil, ...
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT04987229
- Official title
Show the full official title
Long-term, Safety Extension Study of OLZ/SAM in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Little Rock, United States · Stanford, United States
30 more locations
- Washington D.C., United States
- Miami Lakes, United States
- Decatur, United States
- Chicago, United States
- Indianapolis, United States
- Saint Charles, United States
- Lincoln, United States
- New York, United States
- Cincinnati, United States
- West Chester, United States
- Richmond, United States
- Everett, United States
- Ciudad Autonoma de Buenos Aire, Argentina
- La Plata, Argentina
- Buenos Aires, Argentina
- Mendoza, Argentina
- Córdoba, Argentina
- Fortaleza, Brazil
- Curitiba, Brazil
- Rio de Janeiro, Brazil
- São Paulo, Brazil
- Goiânia, Brazil
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Pereira, Colombia
- León, Mexico
- Monterrey, Mexico
- Culiacán, Mexico
- Gustavo A. Madero, Mexico
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Alkermes, Inc.
Does this study involve medication?
Yes. The study involves medication, including OLZ/SAM.
Who can participate?
Listed age limits: 10 years to 17 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
